Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country

Table 4 Relapse according to patient characteristics at baseline (n = 283) n (%)

	Relapse (n = 49)	No relapse (n = 234)	P value
Relapse	49 (17.3)	234 (82.7)
Demographics
Sex
Male	14 (12.4)	99 (87.6)	0.074
Female	35 (20.6)	135 (79.4)
Age
mean ± SD	50.4 ± 8.5	46.0 ± 10.2	0.006
Median (range)	50.00 (34.0-66.0)	48.00 (11.0-68.0)	0.011
≤ 20	0 (0)	4 (100)	0.013
21-40	7 (10.9)	57 (89.1)
41-60	34 (17.3)	162 (82.7)
> 60	8 (42.1)	11 (57.9)
Pre-treatment/comorbidities
HCV/HIV coinfection	0 (0)	3 (100)	0.426
Diabetes mellitus	2 (8.7)	21 (91.3)	0.254
Previous alcohol consumption	9 (17.0)	44 (83.0)	0.943
High pretreatment ALT (> 40)	36 (17.9)	165 (82.1)	0.678
High pretreatment Hgb (≥ 12g/dL)	40 (18.3)	179 (81.7)	0.434
High pretreatment WBC (≥ 4000 mm3)	45 (16.9)	222 (83.1)	0.403
High pretreatment platelet (≥ 150000/mm3)	32 (14.7)	186 (85.3)	0.032
High pretreatment albumin (≥ 3.5 g/dL)	37 (15.0)	209 (85.0)	0.009
High pretreatment HCV RNA (≥ 800000 IU/mL)	36 (20.3)	141 (79.7)	0.082
Liver stiffness
F ≤ 2	9 (6.5)	130 (93.5)	< 0.001
F3-4	40 (27.8)	104 (72.2)
IL28B polymorphism
rs8099917TT	42 (17.3)	201 (82.7)	0.592
rs8099917Non-TT	5 (21.7)	18 (78.3)
Unknown	2 (11.8)	15 (88.2)	0.918
rs12979860CC	40 (17.2)	193 (82.8)	0.569